NO328546B1 - Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og farmasoytiske preparater omfattende slike. - Google Patents

Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og farmasoytiske preparater omfattende slike. Download PDF

Info

Publication number: NO328546B1
Authority: NO; Norway
Prior art keywords: formula; ethyl; phenyl; compound; group
Prior art date: 2000-06-06

Application number

NO20025810A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025810D0 (no

NO20025810L (no

Inventor

Otmar Klingler

Hans Matter

Manfred Schudok

Hans-Peter Nestler

Herman Schreuder

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-06

Filing date

2002-12-03

Publication date

2010-03-15

2002-12-03 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2002-12-03 Publication of NO20025810D0 publication Critical patent/NO20025810D0/no

2002-12-03 Publication of NO20025810L publication Critical patent/NO20025810L/no

2010-03-15 Publication of NO328546B1 publication Critical patent/NO328546B1/no

Links

238000002360 preparation method Methods 0.000 title claims description 8
230000002401 inhibitory effect Effects 0.000 title description 12
229940012414 factor viia Drugs 0.000 title description 5
239000008194 pharmaceutical composition Substances 0.000 title description 2
150000003672 ureas Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 195
-1 phenyloxycarbonyl- Chemical group 0.000 claims description 81
150000003839 salts Chemical class 0.000 claims description 49
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 36
238000000034 method Methods 0.000 claims description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
125000001424 substituent group Chemical group 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 25
230000023555 blood coagulation Effects 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 20
229910052739 hydrogen Inorganic materials 0.000 claims description 20
230000015572 biosynthetic process Effects 0.000 claims description 16
230000005764 inhibitory process Effects 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 14
239000000825 pharmaceutical preparation Substances 0.000 claims description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
239000003112 inhibitor Substances 0.000 claims description 10
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
239000002243 precursor Substances 0.000 claims description 7
208000001435 Thromboembolism Diseases 0.000 claims description 6
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
150000001409 amidines Chemical class 0.000 claims description 5
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 5
125000000524 functional group Chemical group 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 4
150000001721 carbon Chemical group 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 4
239000012948 isocyanate Substances 0.000 claims description 4
150000002513 isocyanates Chemical class 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
230000009467 reduction Effects 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 3
125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims description 3
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000003386 piperidinyl group Chemical group 0.000 claims description 3
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 3
239000004202 carbamide Substances 0.000 claims description 2
230000028709 inflammatory response Effects 0.000 claims description 2
101150115538 nero gene Proteins 0.000 claims description 2
230000000269 nucleophilic effect Effects 0.000 claims description 2
125000004043 oxo group Chemical group O=* 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
125000002757 morpholinyl group Chemical group 0.000 claims 1
125000005936 piperidyl group Chemical group 0.000 claims 1
125000000335 thiazolyl group Chemical group 0.000 claims 1
239000000243 solution Substances 0.000 description 59
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
239000002904 solvent Substances 0.000 description 37
238000004949 mass spectrometry Methods 0.000 description 30
230000000694 effects Effects 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
239000002253 acid Substances 0.000 description 19
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 17
229940088598 enzyme Drugs 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
239000002244 precipitate Substances 0.000 description 15
108090000190 Thrombin Proteins 0.000 description 14
230000015271 coagulation Effects 0.000 description 14
238000005345 coagulation Methods 0.000 description 14
229960004072 thrombin Drugs 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
229920006395 saturated elastomer Polymers 0.000 description 13
108010074860 Factor Xa Proteins 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
108010000499 Thromboplastin Proteins 0.000 description 11
102000002262 Thromboplastin Human genes 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
238000003556 assay Methods 0.000 description 10
239000000543 intermediate Substances 0.000 description 10
238000011321 prophylaxis Methods 0.000 description 10
239000000758 substrate Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
229960002897 heparin Drugs 0.000 description 9
229920000669 heparin Polymers 0.000 description 9
238000003756 stirring Methods 0.000 description 9
239000000126 substance Substances 0.000 description 9
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
208000032843 Hemorrhage Diseases 0.000 description 8
125000003277 amino group Chemical group 0.000 description 8
208000034158 bleeding Diseases 0.000 description 8
230000000740 bleeding effect Effects 0.000 description 8
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
229910000041 hydrogen chloride Inorganic materials 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
208000007536 Thrombosis Diseases 0.000 description 7
239000003146 anticoagulant agent Substances 0.000 description 7
229940127219 anticoagulant drug Drugs 0.000 description 7
238000005859 coupling reaction Methods 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000020764 fibrinolysis Effects 0.000 description 6
239000008177 pharmaceutical agent Substances 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 5
125000002015 acyclic group Chemical group 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
125000000320 amidine group Chemical group 0.000 description 5
239000000872 buffer Substances 0.000 description 5
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000003826 tablet Substances 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
108010054265 Factor VIIa Proteins 0.000 description 4
108010088842 Fibrinolysin Proteins 0.000 description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
206010047249 Venous thrombosis Diseases 0.000 description 4
230000004913 activation Effects 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
150000001450 anions Chemical class 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
125000000753 cycloalkyl group Chemical group 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000012071 phase Substances 0.000 description 4
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
229940012957 plasmin Drugs 0.000 description 4
230000002265 prevention Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 3
YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
150000008574 D-amino acids Chemical class 0.000 description 3
206010051055 Deep vein thrombosis Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
108010061932 Factor VIIIa Proteins 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000654 additive Substances 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
125000006165 cyclic alkyl group Chemical group 0.000 description 3
230000006624 extrinsic pathway Effects 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
239000003055 low molecular weight heparin Substances 0.000 description 3
229940127215 low-molecular weight heparin Drugs 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
230000037361 pathway Effects 0.000 description 3
108010014806 prothrombinase complex Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
CFAQHXGFQXKEAF-NSHDSACASA-N (2s)-2-[(4-carbamimidoylphenyl)carbamoylamino]-n-[(4-carbamimidoylphenyl)methyl]propanamide Chemical compound N([C@@H](C)C(=O)NCC=1C=CC(=CC=1)C(N)=N)C(=O)NC1=CC=C(C(N)=N)C=C1 CFAQHXGFQXKEAF-NSHDSACASA-N 0.000 description 2
125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 2
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
GJJHHZZKVHQJHG-UHFFFAOYSA-N 2-[(4-carbamimidoylphenyl)carbamoylamino]-n-[(3,4-dichlorophenyl)methyl]acetamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)NCC(=O)NCC1=CC=C(Cl)C(Cl)=C1 GJJHHZZKVHQJHG-UHFFFAOYSA-N 0.000 description 2
ZAYODXWDAFOKRU-UHFFFAOYSA-N 2-[(4-carbamimidoylphenyl)carbamoylamino]-n-[[4-(dimethylamino)phenyl]methyl]-3-phenylpropanamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C(NC(=O)NC=1C=CC(=CC=1)C(N)=N)CC1=CC=CC=C1 ZAYODXWDAFOKRU-UHFFFAOYSA-N 0.000 description 2
PDJZOFLRRJQYBF-UHFFFAOYSA-N 4-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(CN)C=C1 PDJZOFLRRJQYBF-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
241000282520 Papio Species 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
150000003869 acetamides Chemical class 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000003130 blood coagulation factor inhibitor Substances 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
OUSATUZVYOZSMO-UHFFFAOYSA-N ethyl 2-[(4-carbamimidoylphenyl)carbamoylamino]acetate Chemical compound CCOC(=O)CNC(=O)NC1=CC=C(C(N)=N)C=C1 OUSATUZVYOZSMO-UHFFFAOYSA-N 0.000 description 2
DUVOZUPPHBRJJO-UHFFFAOYSA-N ethyl 2-isocyanatoacetate Chemical compound CCOC(=O)CN=C=O DUVOZUPPHBRJJO-UHFFFAOYSA-N 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
239000007789 gas Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000006623 intrinsic pathway Effects 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
FSCRNHORKPOZOC-UHFFFAOYSA-N n-[4-[1-[[2-[(4-carbamimidoylphenyl)carbamoylamino]acetyl]amino]ethyl]phenyl]piperidine-4-carboxamide Chemical compound C=1C=C(NC(=O)C2CCNCC2)C=CC=1C(C)NC(=O)CNC(=O)NC1=CC=C(C(N)=N)C=C1 FSCRNHORKPOZOC-UHFFFAOYSA-N 0.000 description 2
XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
UZDDXUMOXKDXNE-QMMMGPOBSA-N (1s)-1-(4-methylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(C)C=C1 UZDDXUMOXKDXNE-QMMMGPOBSA-N 0.000 description 1
XHTORJWGZKCDGL-GRGSLBFTSA-N (2s)-1-[(2r,3r)-2-amino-3-methylpentanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 XHTORJWGZKCDGL-GRGSLBFTSA-N 0.000 description 1
CIXRLEQLNPIEOX-ZDUSSCGKSA-N (2s)-2-[(4-cyanophenyl)carbamoylamino]-n-[(4-cyanophenyl)methyl]propanamide Chemical compound N([C@@H](C)C(=O)NCC=1C=CC(=CC=1)C#N)C(=O)NC1=CC=C(C#N)C=C1 CIXRLEQLNPIEOX-ZDUSSCGKSA-N 0.000 description 1
FBQFZUWRPKZQGW-ZETCQYMHSA-N (2s)-2-[(4-cyanophenyl)carbamoylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)NC1=CC=C(C#N)C=C1 FBQFZUWRPKZQGW-ZETCQYMHSA-N 0.000 description 1
IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
ASVHKWXLEIPBTN-SFHVURJKSA-N (4-methoxyphenyl) (nz)-n-[amino-[4-[[2-[[(1s)-1-(4-methylphenyl)ethyl]amino]-2-oxoethyl]carbamoylamino]phenyl]methylidene]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NC(=N)C(C=C1)=CC=C1NC(=O)NCC(=O)N[C@@H](C)C1=CC=C(C)C=C1 ASVHKWXLEIPBTN-SFHVURJKSA-N 0.000 description 1
CCFSGQKTSBIIHG-UHFFFAOYSA-N (4-methoxyphenyl) carbonochloridate Chemical compound COC1=CC=C(OC(Cl)=O)C=C1 CCFSGQKTSBIIHG-UHFFFAOYSA-N 0.000 description 1
ZYWVMTMXQZPJRG-SJCJKPOMSA-N (4s)-5-[[(1s)-1-(3-bromophenyl)ethyl]amino]-4-[(4-carbamimidoylphenyl)carbamoylamino]-5-oxopentanoic acid Chemical compound N([C@@H](CCC(O)=O)C(=O)N[C@@H](C)C=1C=C(Br)C=CC=1)C(=O)NC1=CC=C(C(N)=N)C=C1 ZYWVMTMXQZPJRG-SJCJKPOMSA-N 0.000 description 1
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
XBIAGSJDARBSKG-UHFFFAOYSA-N 1-hydroxypyrrole Chemical compound ON1C=CC=C1 XBIAGSJDARBSKG-UHFFFAOYSA-N 0.000 description 1
125000004804 1-methylmethylene group Chemical group [H]C([H])([H])C([H])([*:2])[*:1] 0.000 description 1
AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 description 1
YXGOZOSEKVRVRX-ZDUSSCGKSA-N 2-[(4-carbamimidoylphenyl)carbamoyl-hydroxyamino]-n-[(1s)-1-(4-methylphenyl)ethyl]acetamide Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(=O)CN(O)C(=O)NC1=CC=C(C(N)=N)C=C1 YXGOZOSEKVRVRX-ZDUSSCGKSA-N 0.000 description 1
TYNDDVKAZVDIHI-IBGZPJMESA-N 2-[(4-carbamimidoylphenyl)carbamoyl-phenylmethoxyamino]-n-[(1s)-1-(4-methylphenyl)ethyl]acetamide Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(=O)CN(C(=O)NC=1C=CC(=CC=1)C(N)=N)OCC1=CC=CC=C1 TYNDDVKAZVDIHI-IBGZPJMESA-N 0.000 description 1
WUFPCUQYRKZYRH-UHFFFAOYSA-N 2-[(4-carbamimidoylphenyl)carbamoylamino]-n-[(3-chlorophenyl)methyl]acetamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)NCC(=O)NCC1=CC=CC(Cl)=C1 WUFPCUQYRKZYRH-UHFFFAOYSA-N 0.000 description 1
DHLWVZIHLVZPDF-UHFFFAOYSA-N 2-[(4-carbamimidoylphenyl)carbamoylamino]-n-[[4-(dimethylamino)phenyl]methyl]acetamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)CNC(=O)NC1=CC=C(C(N)=N)C=C1 DHLWVZIHLVZPDF-UHFFFAOYSA-N 0.000 description 1
PZOAPWNTDAJICZ-UHFFFAOYSA-N 2-[(4-carbamimidoylphenyl)carbamoylamino]acetic acid Chemical compound NC(=N)C1=CC=C(NC(=O)NCC(O)=O)C=C1 PZOAPWNTDAJICZ-UHFFFAOYSA-N 0.000 description 1
HKGQRPQEDIWXNI-FQEVSTJZSA-N 2-[(4-cyanophenyl)carbamoyl-phenylmethoxyamino]-n-[(1s)-1-(4-methylphenyl)ethyl]acetamide Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(=O)CN(C(=O)NC=1C=CC(=CC=1)C#N)OCC1=CC=CC=C1 HKGQRPQEDIWXNI-FQEVSTJZSA-N 0.000 description 1
YXJNKHACXWCCLM-UHFFFAOYSA-N 2-[(4-cyanophenyl)carbamoyl-phenylmethoxyamino]acetic acid Chemical compound C=1C=C(C#N)C=CC=1NC(=O)N(CC(=O)O)OCC1=CC=CC=C1 YXJNKHACXWCCLM-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
TVSXDZNUTPLDKY-UHFFFAOYSA-N 4-isocyanatobenzonitrile Chemical compound O=C=NC1=CC=C(C#N)C=C1 TVSXDZNUTPLDKY-UHFFFAOYSA-N 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
125000004399 C1-C4 alkenyl group Chemical group 0.000 description 1
125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241001146702 Candidatus Entotheonella factor Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
241000854350 Enicospilus group Species 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010012088 Fibrinogen Receptors Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007821 HATU Substances 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
102100025306 Integrin alpha-IIb Human genes 0.000 description 1
101710149643 Integrin alpha-IIb Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
VLCARLJGRUWNPS-VIFPVBQESA-N NC(=N)C1=CC=C(NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 Chemical compound NC(=N)C1=CC=C(NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VLCARLJGRUWNPS-VIFPVBQESA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000019568 aromas Nutrition 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012267 brine Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
AVDNGGJZZVTQNA-UHFFFAOYSA-N di(pyrrol-1-yl)methanone Chemical compound C1=CC=CN1C(=O)N1C=CC=C1 AVDNGGJZZVTQNA-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
KRJGZVIQULVNJP-VIFPVBQESA-N ethyl (2s)-2-[(4-cyanophenyl)carbamoylamino]propanoate Chemical compound CCOC(=O)[C@H](C)NC(=O)NC1=CC=C(C#N)C=C1 KRJGZVIQULVNJP-VIFPVBQESA-N 0.000 description 1
ROBXZHNBBCHEIQ-BYPYZUCNSA-N ethyl (2s)-2-aminopropanoate Chemical compound CCOC(=O)[C@H](C)N ROBXZHNBBCHEIQ-BYPYZUCNSA-N 0.000 description 1
MNGJQFDGJSTLBR-UHFFFAOYSA-N ethyl 2-[(4-carbamimidoylphenyl)carbamoylamino]-3-phenylpropanoate Chemical compound C=1C=C(C(N)=N)C=CC=1NC(=O)NC(C(=O)OCC)CC1=CC=CC=C1 MNGJQFDGJSTLBR-UHFFFAOYSA-N 0.000 description 1
MIYNHSDQFSDYRP-UHFFFAOYSA-N ethyl 2-[(4-cyanophenyl)carbamoylamino]-3-phenylpropanoate Chemical compound C=1C=C(C#N)C=CC=1NC(=O)NC(C(=O)OCC)CC1=CC=CC=C1 MIYNHSDQFSDYRP-UHFFFAOYSA-N 0.000 description 1
CLTKKPRUJDXJOF-UHFFFAOYSA-N ethyl 2-[(4-cyanophenyl)carbamoylamino]acetate Chemical compound CCOC(=O)CNC(=O)NC1=CC=C(C#N)C=C1 CLTKKPRUJDXJOF-UHFFFAOYSA-N 0.000 description 1
XPTULGKOMJENCO-UHFFFAOYSA-N ethyl 2-[[4-(c-ethoxycarbonimidoyl)phenyl]carbamoylamino]acetate Chemical compound CCOC(=O)CNC(=O)NC1=CC=C(C(=N)OCC)C=C1 XPTULGKOMJENCO-UHFFFAOYSA-N 0.000 description 1
FRRKLSBTCHDJIC-UHFFFAOYSA-N ethyl 2-[[4-[n'-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]phenyl]carbamoylamino]acetate Chemical compound CCOC(=O)CNC(=O)NC1=CC=C(C(=N)NC(=O)OC(C)(C)C)C=C1 FRRKLSBTCHDJIC-UHFFFAOYSA-N 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
108091006086 inhibitor proteins Proteins 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
108010075079 isoleucyl-prolyl-arginine-4-nitroanilide Proteins 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000012933 kinetic analysis Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
CVCMDSPOHSKOKC-JTQLQIEISA-N n-[(1s)-1-(3-bromophenyl)ethyl]-2-[(4-carbamimidoyl-3-fluorophenyl)carbamoylamino]acetamide Chemical compound N([C@@H](C)C=1C=C(Br)C=CC=1)C(=O)CNC(=O)NC1=CC=C(C(N)=N)C(F)=C1 CVCMDSPOHSKOKC-JTQLQIEISA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
QZRXRMPNCPCMSW-UHFFFAOYSA-N phosphanyl(phosphanylidene)phosphane Chemical compound PP=P QZRXRMPNCPCMSW-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
ZDPUIQSOFNLZFA-UHFFFAOYSA-M sodium;2-[[4-[(e)-n'-[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]phenyl]carbamoylamino]acetate Chemical compound [Na+].CC(C)(C)OC(=O)\N=C(/N)C1=CC=C(NC(=O)NCC([O-])=O)C=C1 ZDPUIQSOFNLZFA-UHFFFAOYSA-M 0.000 description 1
VAYLTNXXQRZFMH-UHFFFAOYSA-M sodium;2-[[4-[n,n'-bis[(2-methylpropan-2-yl)oxycarbonyl]carbamimidoyl]phenyl]carbamoylamino]-3-phenylpropanoate Chemical compound [Na+].C1=CC(C(=NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)=CC=C1NC(=O)NC(C([O-])=O)CC1=CC=CC=C1 VAYLTNXXQRZFMH-UHFFFAOYSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
PREYMAMVGNRZDT-UHFFFAOYSA-N tert-butyl 2-[(4-cyanophenyl)carbamoyl-phenylmethoxyamino]acetate Chemical compound C=1C=C(C#N)C=CC=1NC(=O)N(CC(=O)OC(C)(C)C)OCC1=CC=CC=C1 PREYMAMVGNRZDT-UHFFFAOYSA-N 0.000 description 1
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
SBCPQRVZOINKOO-UHFFFAOYSA-N tert-butyl 4-[(4-acetylphenyl)carbamoyl]piperidine-1-carboxylate Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 SBCPQRVZOINKOO-UHFFFAOYSA-N 0.000 description 1
ZXTWSAFPBMHPQC-UHFFFAOYSA-N tert-butyl 4-[[4-(1-aminoethyl)phenyl]carbamoyl]piperidine-1-carboxylate Chemical compound C1=CC(C(N)C)=CC=C1NC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 ZXTWSAFPBMHPQC-UHFFFAOYSA-N 0.000 description 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
125000005500 uronium group Chemical group 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes

NO20025810A 2000-06-06 2002-12-03 Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og farmasoytiske preparater omfattende slike. NO328546B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00112116A EP1162194A1 (en)	2000-06-06	2000-06-06	Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PCT/EP2001/006029 WO2001094301A2 (en)	2000-06-06	2001-05-26	Factor viia inhibitory (thio)urea derivatives, their preparation and their use

Publications (3)

Publication Number	Publication Date
NO20025810D0 NO20025810D0 (no)	2002-12-03
NO20025810L NO20025810L (no)	2002-12-03
NO328546B1 true NO328546B1 (no)	2010-03-15

Family

ID=8168926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025810A NO328546B1 (no)	2000-06-06	2002-12-03	Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og farmasoytiske preparater omfattende slike.

Country Status (30)

Country	Link
US (1)	US6743790B2 (es)
EP (2)	EP1162194A1 (es)
JP (1)	JP4809570B2 (es)
KR (1)	KR101011345B1 (es)
CN (1)	CN1208314C (es)
AR (1)	AR030936A1 (es)
AU (2)	AU2001277494B2 (es)
BR (1)	BR0111264A (es)
CA (1)	CA2410862C (es)
CZ (1)	CZ20023963A3 (es)
DE (1)	DE60139320D1 (es)
DK (1)	DK1299354T3 (es)
EE (1)	EE200200617A (es)
ES (1)	ES2330412T3 (es)
HK (1)	HK1055941A1 (es)
HR (1)	HRP20020961A2 (es)
HU (1)	HUP0301631A2 (es)
IL (2)	IL153220A0 (es)
MX (1)	MXPA02009789A (es)
MY (1)	MY129363A (es)
NO (1)	NO328546B1 (es)
NZ (1)	NZ522960A (es)
PL (1)	PL359584A1 (es)
PT (1)	PT1299354E (es)
RU (1)	RU2286337C2 (es)
SK (1)	SK17032002A3 (es)
TW (1)	TWI283662B (es)
WO (1)	WO2001094301A2 (es)
YU (1)	YU89202A (es)
ZA (1)	ZA200209018B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183277B2 (en)	2002-04-27	2007-02-27	Merck Patent Gmbh	Carboxylic acid amides
JP2005535710A (ja) *	2002-08-09	2005-11-24	トランス　テック　ファーマ，インコーポレイテッド	アリールおよびヘテロアリール化合物ならびに凝固を調節する方法
EP1626966A1 (en) *	2003-05-20	2006-02-22	Genentech, Inc.	Benzofuran inhibitors of factor viia
CA2525854C (en) *	2003-05-20	2009-12-15	Genentech, Inc.	Acylsulfamide inhibitors of factor viia
CA2531796A1 (en) *	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) *	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) *	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
WO2006041119A1 (ja) *	2004-10-13	2006-04-20	Eisai R & D Management Co., Ltd.	ヒドラジド誘導体
TW200630337A (en) *	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
US20090130085A1 (en) *	2005-02-24	2009-05-21	Novo Nordish Healthcare Ag	Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations
EP1855722A2 (en) *	2005-02-24	2007-11-21	Novo Nordisk Health Care AG	Compounds for stabilizing factor vii polypeptide formulations
EP1856091A1 (en) *	2005-02-24	2007-11-21	Novo Nordisk Health Care AG	Compounds for stabilizing factor vii polypeptide formulations
US8633300B2 (en)	2005-06-17	2014-01-21	Novo Nordisk Healthcare Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
DE602007011231D1 (de)	2006-03-24	2011-01-27	Eisai R&D Man Co Ltd	Triazolonderivat
US8247442B2 (en) *	2006-03-29	2012-08-21	Purdue Pharma L.P.	Benzenesulfonamide compounds and their use
WO2007118854A1 (en) *	2006-04-13	2007-10-25	Euro-Celtique S.A.	Benzenesulfonamide compounds and the use thereof
TW200815353A (en) *	2006-04-13	2008-04-01	Euro Celtique Sa	Benzenesulfonamide compounds and their use
WO2008124118A1 (en) *	2007-04-09	2008-10-16	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use therof
EP2202231A4 (en)	2007-09-21	2011-09-28	Eisai R&D Man Co Ltd	2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
US8765736B2 (en) *	2007-09-28	2014-07-01	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
CN104114164B (zh)	2011-10-26	2016-11-16	阿勒根公司	作为甲酰肽受体样-1(fprl-1)受体调节剂的n-脲取代的氨基酸的酰胺衍生物
WO2013158597A1 (en) *	2012-04-16	2013-10-24	Allergan, Inc.	(2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
JP2015534573A (ja)	2012-10-10	2015-12-03	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	第ｖｉｉ因子ポリペプチドの液体医薬組成物
CA3114477A1 (en)	2013-03-06	2014-09-12	Allergan, Inc.	Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
CN110279684B (zh)	2013-03-06	2023-02-28	阿勒根公司	用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5273982A (en) *	1990-03-09	1993-12-28	Hoffmann-La Roche Inc.	Acetic acid derivatives
US5506134A (en)	1990-10-22	1996-04-09	Corvas International, Inc.	Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
WO1992013552A1 (en) *	1991-02-05	1992-08-20	Smithkline Beecham Corporation	Anti-aggregatory peptides containing an aromatic ester or amide
US5788965A (en)	1991-02-28	1998-08-04	Novo Nordisk A/S	Modified factor VII
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
JP3387948B2 (ja) *	1992-12-04	2003-03-17	富山化学工業株式会社	新規なフェニルアラニン誘導体またはその塩
US5314902A (en) *	1993-01-27	1994-05-24	Monsanto Company	Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) *	1993-03-26	1994-09-29	Cassella Ag	Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313269D0 (en) *	1993-06-28	1993-08-11	Zeneca Ltd	Allophanic acid derivatives
GB9313268D0 (en) *	1993-06-28	1993-08-11	Zeneca Ltd	Chemical compounds
WO1995008550A1 (en) *	1993-09-24	1995-03-30	Abbott Laboratories	Endothelin antagonists
CA2174516A1 (en) *	1993-10-19	1995-04-27	Yoshiharu Ikeda	2,3-diaminopropionic acid derivative
US5674894A (en) *	1995-05-15	1997-10-07	G.D. Searle & Co.	Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
AU712504B2 (en) *	1996-01-30	1999-11-11	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
KR20010032253A (ko) *	1997-11-18	2001-04-16	이타가키 히로시	시클릭 아민 유도체 및 그 약제로서의 용도
EP0987274A1 (en) *	1998-09-15	2000-03-22	Hoechst Marion Roussel Deutschland GmbH	Factor VIIa Inhibitors

2000
- 2000-06-06 EP EP00112116A patent/EP1162194A1/en not_active Withdrawn
2001
- 2001-05-26 MX MXPA02009789A patent/MXPA02009789A/es active IP Right Grant
- 2001-05-26 IL IL15322001A patent/IL153220A0/xx unknown
- 2001-05-26 ES ES01955291T patent/ES2330412T3/es not_active Expired - Lifetime
- 2001-05-26 DK DK01955291T patent/DK1299354T3/da active
- 2001-05-26 AU AU2001277494A patent/AU2001277494B2/en not_active Ceased
- 2001-05-26 EP EP01955291A patent/EP1299354B1/en not_active Expired - Lifetime
- 2001-05-26 BR BR0111264-3A patent/BR0111264A/pt not_active IP Right Cessation
- 2001-05-26 YU YU89202A patent/YU89202A/sh unknown
- 2001-05-26 CZ CZ20023963A patent/CZ20023963A3/cs unknown
- 2001-05-26 JP JP2002501818A patent/JP4809570B2/ja not_active Expired - Fee Related
- 2001-05-26 DE DE60139320T patent/DE60139320D1/de not_active Expired - Lifetime
- 2001-05-26 SK SK1703-2002A patent/SK17032002A3/sk not_active Application Discontinuation
- 2001-05-26 NZ NZ522960A patent/NZ522960A/en unknown
- 2001-05-26 CN CNB018088309A patent/CN1208314C/zh not_active Expired - Fee Related
- 2001-05-26 AU AU7749401A patent/AU7749401A/xx active Pending
- 2001-05-26 KR KR1020027016691A patent/KR101011345B1/ko not_active IP Right Cessation
- 2001-05-26 WO PCT/EP2001/006029 patent/WO2001094301A2/en active IP Right Grant
- 2001-05-26 PT PT01955291T patent/PT1299354E/pt unknown
- 2001-05-26 PL PL01359584A patent/PL359584A1/xx not_active Application Discontinuation
- 2001-05-26 HU HU0301631A patent/HUP0301631A2/hu unknown
- 2001-05-26 RU RU2002135308/04A patent/RU2286337C2/ru not_active IP Right Cessation
- 2001-05-26 CA CA002410862A patent/CA2410862C/en not_active Expired - Fee Related
- 2001-05-26 EE EEP200200617A patent/EE200200617A/xx unknown
- 2001-06-04 TW TW090113412A patent/TWI283662B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102657A patent/AR030936A1/es active IP Right Grant
- 2001-06-05 MY MYPI20012631A patent/MY129363A/en unknown
- 2001-06-06 US US09/874,318 patent/US6743790B2/en not_active Expired - Lifetime
2002
- 2002-11-06 ZA ZA200209018A patent/ZA200209018B/en unknown
- 2002-12-02 IL IL153220A patent/IL153220A/en not_active IP Right Cessation
- 2002-12-03 NO NO20025810A patent/NO328546B1/no not_active IP Right Cessation
- 2002-12-05 HR HRP20020961 patent/HRP20020961A2/hr not_active Application Discontinuation
2003
- 2003-11-12 HK HK03108194A patent/HK1055941A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
MXPA02009789A (es)	2003-03-12
CN1208314C (zh)	2005-06-29
EP1299354A2 (en)	2003-04-09
CA2410862A1 (en)	2001-12-13
AU7749401A (en)	2001-12-17
EP1299354B1 (en)	2009-07-22
TWI283662B (en)	2007-07-11
JP2003535844A (ja)	2003-12-02
AR030936A1 (es)	2003-09-03
US20020052417A1 (en)	2002-05-02
RU2286337C2 (ru)	2006-10-27
ES2330412T3 (es)	2009-12-10
IL153220A (en)	2008-11-03
NO20025810D0 (no)	2002-12-03
KR20030007911A (ko)	2003-01-23
ZA200209018B (en)	2003-10-08
JP4809570B2 (ja)	2011-11-09
WO2001094301A3 (en)	2002-04-04
CN1427818A (zh)	2003-07-02
CA2410862C (en)	2009-11-10
DK1299354T3 (da)	2009-11-16
PT1299354E (pt)	2009-10-01
HUP0301631A2 (hu)	2003-09-29
HK1055941A1 (en)	2004-01-30
HRP20020961A2 (en)	2004-12-31
NO20025810L (no)	2002-12-03
IL153220A0 (en)	2003-07-06
EP1162194A1 (en)	2001-12-12
CZ20023963A3 (cs)	2003-03-12
AU2001277494B2 (en)	2006-05-04
DE60139320D1 (de)	2009-09-03
WO2001094301A2 (en)	2001-12-13
PL359584A1 (en)	2004-08-23
NZ522960A (en)	2004-05-28
EE200200617A (et)	2004-04-15
BR0111264A (pt)	2003-06-17
MY129363A (en)	2007-03-30
US6743790B2 (en)	2004-06-01
SK17032002A3 (sk)	2003-05-02
YU89202A (sh)	2006-05-25
KR101011345B1 (ko)	2011-01-28

Legal Events

Date	Code	Title	Description
2013-12-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO328546B1 (no)	2010-03-15	Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og farmasoytiske preparater omfattende slike.
US6395737B1 (en)	2002-05-28	Malonic acid derivatives, processes for their preparation, for their use and pharmaceutical compositions containing them
US6794365B2 (en)	2004-09-21	Malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them
WO1998016547A1 (en)	1998-04-23	SELECTIVE FACTOR Xa INHIBITORS
WO1999007731A1 (en)	1999-02-18	SELECTIVE FACTOR Xa INHIBITORS
WO1998046626A1 (en)	1998-10-22	SELECTIVE FACTOR Xa INHIBITORS
JP4546683B2 (ja)	2010-09-15	ファクターＶＩＩａ阻害剤
EP1016663A1 (en)	2000-07-05	Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
NO328016B1 (no)	2009-11-09	N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasoytiske preparater omfattende disse
EP0994893B1 (en)	2002-01-02	Selective factor xa inhibitors containing a fused azepinone structure
WO1998046627A1 (en)	1998-10-22	SELECTIVE FACTOR Xa INHIBITORS
US6333321B1 (en)	2001-12-25	Selective factor Xa inhibitors
AU2285700A (en)	2000-07-24	Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
AU720513B2 (en)	2000-06-01	Selective factor Xa inhibitors
AU744626B2 (en)	2002-02-28	Selective factor Xa inhibitors
MXPA01006485A (es)	2001-12-13	Derivados novedosos de acido malonico, procesos para su preparacion su uso y composiciones farmaceuticas que los contienen (inhibicion de actividad de facto xa)
AU5507900A (en)	2001-01-11	Selective factor Xa inhibitors